Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Validation of endoscopic activity scores in patients with Crohn's disease

A post hoc analysis reported in November's issue of Gastroenterology validates endoscopic activity scores in patients with Crohn's disease.

News image

Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in clinical trials.

However, the minimal degree of mucosal improvement (endoscopic response) required to alter midterm outcomes is not known.

Dr Marc Ferrante and colleagues from Belgium determined the best definition of endoscopic response by evaluating data on the Simple Endoscopic Score for Crohn's Disease (SES-CD), and the Crohn's Disease Endoscopic Index of Severity (CDEIS) from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC trial).

The researchers analyzed data from 172 patients who participated in the SONIC trial, were found to have endoscopic lesions at baseline, and underwent a second endoscopic examination at week 26 of treatment with infliximab, azathioprine, or both.

The team defined mucosal healing as absence of ulcers.

The relative risk was 0.80 for an increment of 1 cup of coffee per day
Gastroenterology

A central reader calculated SES-CD and CDEIS results.

Different cutoff values were set for endoscopic response based on the SES-CD or CDEIS.

The diagnostic ability of these different cutoff values was evaluated using receiver operating characteristic curves, positive likelihood ratios, and negative likelihood ratios.

Corticosteroid-free clinical remission (CFREM) at week 50 was used as a binary classifier.

Based on analyses of ROC curves, positive likelihood ratios, and negative likelihood ratios, endoscopic response was defined as a decrease from baseline in SES-CD of at least 50%.

The research team found that at week 26, mucosal healing and endoscopic response were achieved in 48% and 65% of patients, respectively.

Mucosal healing at week 26 was associated with CFREM at week 50, with 56% sensitivity, 65% specificity, a positive likelihood ratios of 1.60, and an negative likelihood ratios of 0.67.

Endoscopic response at week 26 was associated with CFREM at week 50, with 74% sensitivity, 48% specificity, a positive likelihood ratios of 1.42, and an negative likelihood ratios of 0.54.

The team observed that endoscopic response, defined as a decrease from baseline in CDEIS of at least 50%, yielded similar results.

Dr Ferrante's team concludes, "In patients with Crohn's disease, mucosal healing and endoscopic response at week 26 of treatment identified those most likely to be in CFREM at week 50."

"The ability of the proposed endoscopic response cutoff value to predict midterm CFREM should be validated in an independent, prospective cohort."

"Its correlation with changes in long-term disease progression still needs to be demonstration."

Gastroenterol 2013: 145(5): 978-986.e5
25 October 2013

Go to top of page Email this page Email this page to a colleague

 22 July 2016 
Fecal calprotectin and IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Longterm clinical follow-up of living liver donors
 19 July 2016 
Screening diabetic patients for NAFLD
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 18 July 2016 
Liver cancer prediction scores in Hep B
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Treatment of pediatric acute liver failure
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Statins and cirrhosis in Hep B
 08 July 2016 
Genetic risk score and body mass index
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 05 July 2016 
Exercise and gastroesophageal reflux
 04 July 2016 
Guidelines on PPI and NSAID prescription
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 01 July 2016 
Aspirin and colorectal cancer
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 28 June 2016 
Acute severe ulcerative colitis
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
The Toronto Consensus for H. pylori treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us